Concepedia

Xingui Liu

XL

Statistics

Publications

16

Citations

2.1K

H-Index

15

Active since

2014

Affiliations

University of Florida(Current)

University of Arkansas for Medical Sciences

Florida College

The University of Texas at San Antonio Health Science Center

First Affiliated Hospital of Zhengzhou University

Xingui Liu is an author at University of Florida specializing in pharmacology, medicine, and apoptosis.

ORCID

Publications per year

2014–2023

16

Publications

16

A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity

Sajid Khan, Xuan Zhang, Dongwen Lv et al. · Nature Medicine · 2019 · 647 citations · Full text

, , +7

Discovery of piperlongumine as a potential novel lead for the development of senolytic agents

Yingying Wang, Jianhui Chang, Xingui Liu et al. · Aging · 2016 · 269 citations · Full text

, , +15

Using proteolysis-targeting chimera technology to reduce navitoclax platelet toxicity and improve its senolytic activity

Yonghan He, Xuan Zhang, Jianhui Chang et al. · Nature Communications · 2020 · 257 citations · Full text

, , +13

Discovery of XL01126: A Potent, Fast, Cooperative, Selective, Orally Bioavailable, and Blood–Brain Barrier Penetrant PROTAC Degrader of Leucine-Rich Repeat Kinase 2

Xingui Liu, Alexia F. Kalogeropulou, Sofia Domingos et al. · Journal of the American Chemical Society · 2022 · 172 citations · Full text

, , +13

Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,

Dongwen Lv, Pratik Pal, Xingui Liu et al. · Nature Communications · 2021 · 148 citations · Full text

, , +12

1–5 of 16